Em resumo
- 25 to 40% of weight lost on GLP-1 medications is lean mass (muscle) without dietary protein strategy
- STEP 1 trial: semaglutide produced 14.9% average body weight loss over 68 weeks
- Nausea affects 44% of semaglutide users (vs 16% placebo) — primarily during dose escalation
- Whey protein increases GLP-1 by 25 to 50% above baseline — strongest food-based GLP-1 trigger
- Tirzepatide produces ~20 to 22% body weight loss — higher than semaglutide — with similar lean mass considerations
GLP-1 Medication Clinical Trial Key Outcomes
| Medication | Trial | Average body weight reduction | Duration | Lean mass loss estimate |
|---|---|---|---|---|
| Semaglutide 2.4 mg (Wegovy) | STEP 1 | 14.9% of body weight | 68 weeks | 25 to 40% of weight lost from lean mass (without protein strategy) |
| Semaglutide 2.4 mg (Wegovy) | STEP 3 (intensive behavioral) | 16.0% of body weight | 68 weeks | Slightly lower lean mass loss with behavioral counseling |
| Tirzepatide 15 mg (Zepbound) | SURMOUNT-1 | 20.9% of body weight | 72 weeks | Lean mass proportion similar to semaglutide without dietary guidance |
| Liraglutide 3.0 mg (Saxenda) | SCALE trial | 8.0% of body weight | 56 weeks | Similar lean mass loss concern at lower total weight loss |
| Semaglutide (Ozempic 1 mg, type 2 diabetes) | SUSTAIN 6 | 4.5 kg average loss | 104 weeks | Cardiovascular primary endpoint trial; weight was secondary |
Muscle Loss on GLP-1: The Data
The proportion of weight loss attributable to lean mass (muscle, bone, water) versus fat mass is a critical quality measure of weight loss interventions. For context: a diet-induced caloric deficit without exercise typically produces 75 to 80 percent fat loss and 20 to 25 percent lean mass loss. GLP-1 medications without specific protein and exercise guidance produce a higher lean mass proportion.
| Weight loss method | Approximate % from fat | Approximate % from lean mass | Notes |
|---|---|---|---|
| GLP-1 medication (no protein strategy, no exercise) | 60 to 75% | 25 to 40% | Wide variation across trials; higher lean loss than diet alone in some analyses |
| GLP-1 medication + high protein (1.4 g/kg+) | 80 to 90% | 10 to 20% | Significant improvement — protein preserves lean mass during restriction |
| GLP-1 medication + protein + resistance exercise | 85 to 92% | 8 to 15% | Best body composition outcomes; approaches caloric restriction gold standard |
| Moderate caloric restriction, no GLP-1 | 75 to 80% | 20 to 25% | Standard diet reference point |
| Caloric restriction + resistance exercise | 85 to 90% | 10 to 15% | Gold standard comparison |
| Very low calorie diet (below 800 kcal/day) | 50 to 65% | 35 to 50% | High lean mass loss — shows risk of extreme restriction |
